Global Hemostatic Agents

Hemostatic Agents Comprehensive Study by Type (Passive Agents (Collagen, Cellulose, Gelatin, Polysaccharide hemospheres), Active Agents (Thrombin, FloSeal, Sealants), Newer Hemostatic Agents (Chitosan, Hemostatic Solutions)), Application (Cardiology, Trauma, General Surgery, Transplant, Orthopedic, Plastic Surgery, Dental, Others), End-User (Hospitals, Clinics, Ambulatory Surgical Centers) Players and Region - Global Market Outlook to 2030

Hemostatic Agents Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 8.8%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Hemostatic Agents Market Overview:
Hemostasis is defined as the stoppage of bleeding, hemorrhage, or blood flow through a blood vessel or body part. Hemostatic agents improve hemostasis by improving primary hemostasis, stimulating fibrin formation, or inhibiting fibrinolysis. When conventional methods do not control bleeding at that time hemostatic agents are beneficial as adjunctive therapy during surgical procedures. Although rare adverse effects have happened with these agents, their careful administration will avoid serious adverse outcomes. As per latest study released by AMA Research, the Global Hemostatic Agents market is expected to see growth rate of 8.8%

AttributesDetails
Study Period201-2030
Base Year2023
Forecast Period2024-2030
Historical Period201-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Rising Healthcare Expenditures

Market Growth Drivers:
Rise in Surgical Procedures and Increasing the Incidence of Hemorrhage during Surgery

Challenges:
Unintentional Intravascular Clotting Leading to Stroke

Restraints:
High Costs of Surgical Procedures

Opportunities:
Advancements in the Healthcare Facilities

Competitive Landscape:
The global market is highly competitive and consists of a limited number of providers competing. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.
Some of the key players profiled in the report are Johnson & Johnson Services, Inc. (United States), Baxter International Incorporation (United States), C.R. Bard Incorporation (United States), B.Braun Melsungen AG (Germany), Advanced Medical Solutions Group (United Kingdom), CuraMedical B.V. (Netherlands), Stryker (United States), Integra Life Sciences (United States), Becton Dickinson (United States), Pfizer Inc. (United States) and Medtrade Products Ltd (United Kingdom). Additionally, following companies can also be profiled that are part of our coverage like Integra Life Sciences (United States), Medtronic (Ireland), CryoLife Inc. (United States) and LinxObere Medizintechnik GmbH (Germany). Analyst at AMA Research see United States Players to retain maximum share of Global Hemostatic Agents market by 2030. Considering Market by End-User, the sub-segment i.e. Hospitals will boost the Hemostatic Agents market.

Latest Market Insights:
In 2021, Baxter International acquired NxTherapeutics, a developer of innovative hemostatic agents for surgical and interventional procedures. This acquisition strengthened Baxter's portfolio in bleeding management solutions.

In 2023, Medtronic launched its next-generation hemostatic patch, Tachosil Fibrin Sealant Patch, designed for broader surgical applications. This product offers faster application and improved handling compared to previous versions.

What Can be Explored with the Hemostatic Agents Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Hemostatic Agents Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Hemostatic Agents
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Hemostatic Agents market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Hemostatic Agents market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Hemostatic Agents, Suppliers of Hemostatic Agents, Wholesalers, Distributors and Retailers of Hemostatic Agents, Healthcare Industry, Research Firms and Governmental Bodies.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Passive Agents [Collagen, Cellulose, Gelatin, Polysaccharide hemospheres]
  • Active Agents [Thrombin, FloSeal, Sealants]
  • Newer Hemostatic Agents [Chitosan, Hemostatic Solutions]
By Application
  • Cardiology
  • Trauma
  • General Surgery
  • Transplant
  • Orthopedic
  • Plastic Surgery
  • Dental
  • Others
By End-User
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in Surgical Procedures
      • 3.2.2. Increasing the Incidence of Hemorrhage during Surgery
    • 3.3. Market Challenges
      • 3.3.1. Unintentional Intravascular Clotting Leading to Stroke
    • 3.4. Market Trends
      • 3.4.1. Rising Healthcare Expenditures
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hemostatic Agents, by Type, Application, End-User and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hemostatic Agents (Value)
      • 5.2.1. Global Hemostatic Agents by: Type (Value)
        • 5.2.1.1. Passive Agents [Collagen, Cellulose, Gelatin, Polysaccharide hemospheres]
        • 5.2.1.2. Active Agents [Thrombin, FloSeal, Sealants]
        • 5.2.1.3. Newer Hemostatic Agents [Chitosan, Hemostatic Solutions]
      • 5.2.2. Global Hemostatic Agents by: Application (Value)
        • 5.2.2.1. Cardiology
        • 5.2.2.2. Trauma
        • 5.2.2.3. General Surgery
        • 5.2.2.4. Transplant
        • 5.2.2.5. Orthopedic
        • 5.2.2.6. Plastic Surgery
        • 5.2.2.7. Dental
        • 5.2.2.8. Others
      • 5.2.3. Global Hemostatic Agents by: End-User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Ambulatory Surgical Centers
      • 5.2.4. Global Hemostatic Agents Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Hemostatic Agents (Volume)
      • 5.3.1. Global Hemostatic Agents by: Type (Volume)
        • 5.3.1.1. Passive Agents [Collagen, Cellulose, Gelatin, Polysaccharide hemospheres]
        • 5.3.1.2. Active Agents [Thrombin, FloSeal, Sealants]
        • 5.3.1.3. Newer Hemostatic Agents [Chitosan, Hemostatic Solutions]
      • 5.3.2. Global Hemostatic Agents by: Application (Volume)
        • 5.3.2.1. Cardiology
        • 5.3.2.2. Trauma
        • 5.3.2.3. General Surgery
        • 5.3.2.4. Transplant
        • 5.3.2.5. Orthopedic
        • 5.3.2.6. Plastic Surgery
        • 5.3.2.7. Dental
        • 5.3.2.8. Others
      • 5.3.3. Global Hemostatic Agents by: End-User (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Clinics
        • 5.3.3.3. Ambulatory Surgical Centers
      • 5.3.4. Global Hemostatic Agents Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Hemostatic Agents (Price)
      • 5.4.1. Global Hemostatic Agents by: Type (Price)
  • 6. Hemostatic Agents: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson & Johnson Services, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Baxter International Incorporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. C.R. Bard Incorporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. B.Braun Melsungen AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Advanced Medical Solutions Group (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. CuraMedical B.V. (Netherlands)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Stryker (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Integra Life Sciences (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Becton Dickinson (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Medtrade Products Ltd (United Kingdom)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Hemostatic Agents Sale, by Type, Application, End-User and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hemostatic Agents (Value)
      • 7.2.1. Global Hemostatic Agents by: Type (Value)
        • 7.2.1.1. Passive Agents [Collagen, Cellulose, Gelatin, Polysaccharide hemospheres]
        • 7.2.1.2. Active Agents [Thrombin, FloSeal, Sealants]
        • 7.2.1.3. Newer Hemostatic Agents [Chitosan, Hemostatic Solutions]
      • 7.2.2. Global Hemostatic Agents by: Application (Value)
        • 7.2.2.1. Cardiology
        • 7.2.2.2. Trauma
        • 7.2.2.3. General Surgery
        • 7.2.2.4. Transplant
        • 7.2.2.5. Orthopedic
        • 7.2.2.6. Plastic Surgery
        • 7.2.2.7. Dental
        • 7.2.2.8. Others
      • 7.2.3. Global Hemostatic Agents by: End-User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Ambulatory Surgical Centers
      • 7.2.4. Global Hemostatic Agents Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Hemostatic Agents (Volume)
      • 7.3.1. Global Hemostatic Agents by: Type (Volume)
        • 7.3.1.1. Passive Agents [Collagen, Cellulose, Gelatin, Polysaccharide hemospheres]
        • 7.3.1.2. Active Agents [Thrombin, FloSeal, Sealants]
        • 7.3.1.3. Newer Hemostatic Agents [Chitosan, Hemostatic Solutions]
      • 7.3.2. Global Hemostatic Agents by: Application (Volume)
        • 7.3.2.1. Cardiology
        • 7.3.2.2. Trauma
        • 7.3.2.3. General Surgery
        • 7.3.2.4. Transplant
        • 7.3.2.5. Orthopedic
        • 7.3.2.6. Plastic Surgery
        • 7.3.2.7. Dental
        • 7.3.2.8. Others
      • 7.3.3. Global Hemostatic Agents by: End-User (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Clinics
        • 7.3.3.3. Ambulatory Surgical Centers
      • 7.3.4. Global Hemostatic Agents Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Hemostatic Agents (Price)
      • 7.4.1. Global Hemostatic Agents by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hemostatic Agents: by Type(USD Million)
  • Table 2. Hemostatic Agents Passive Agents [Collagen, Cellulose, Gelatin, Polysaccharide hemospheres] , by Region USD Million (2018-2023)
  • Table 3. Hemostatic Agents Active Agents [Thrombin, FloSeal, Sealants] , by Region USD Million (2018-2023)
  • Table 4. Hemostatic Agents Newer Hemostatic Agents [Chitosan, Hemostatic Solutions] , by Region USD Million (2018-2023)
  • Table 5. Hemostatic Agents: by Application(USD Million)
  • Table 6. Hemostatic Agents Cardiology , by Region USD Million (2018-2023)
  • Table 7. Hemostatic Agents Trauma , by Region USD Million (2018-2023)
  • Table 8. Hemostatic Agents General Surgery , by Region USD Million (2018-2023)
  • Table 9. Hemostatic Agents Transplant , by Region USD Million (2018-2023)
  • Table 10. Hemostatic Agents Orthopedic , by Region USD Million (2018-2023)
  • Table 11. Hemostatic Agents Plastic Surgery , by Region USD Million (2018-2023)
  • Table 12. Hemostatic Agents Dental , by Region USD Million (2018-2023)
  • Table 13. Hemostatic Agents Others , by Region USD Million (2018-2023)
  • Table 14. Hemostatic Agents: by End-User(USD Million)
  • Table 15. Hemostatic Agents Hospitals , by Region USD Million (2018-2023)
  • Table 16. Hemostatic Agents Clinics , by Region USD Million (2018-2023)
  • Table 17. Hemostatic Agents Ambulatory Surgical Centers , by Region USD Million (2018-2023)
  • Table 18. South America Hemostatic Agents, by Country USD Million (2018-2023)
  • Table 19. South America Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 20. South America Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 21. South America Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 22. Brazil Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 23. Brazil Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 24. Brazil Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 25. Argentina Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 26. Argentina Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 27. Argentina Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 28. Rest of South America Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 29. Rest of South America Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 30. Rest of South America Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 31. Asia Pacific Hemostatic Agents, by Country USD Million (2018-2023)
  • Table 32. Asia Pacific Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 33. Asia Pacific Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 34. Asia Pacific Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 35. China Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 36. China Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 37. China Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 38. Japan Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 39. Japan Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 40. Japan Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 41. India Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 42. India Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 43. India Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 44. South Korea Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 45. South Korea Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 46. South Korea Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 47. Taiwan Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 48. Taiwan Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 49. Taiwan Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 50. Australia Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 51. Australia Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 52. Australia Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 54. Rest of Asia-Pacific Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 55. Rest of Asia-Pacific Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 56. Europe Hemostatic Agents, by Country USD Million (2018-2023)
  • Table 57. Europe Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 58. Europe Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 59. Europe Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 60. Germany Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 61. Germany Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 62. Germany Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 63. France Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 64. France Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 65. France Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 66. Italy Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 67. Italy Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 68. Italy Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 69. United Kingdom Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 70. United Kingdom Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 71. United Kingdom Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 72. Netherlands Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 73. Netherlands Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 74. Netherlands Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 75. Rest of Europe Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 76. Rest of Europe Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 77. Rest of Europe Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 78. MEA Hemostatic Agents, by Country USD Million (2018-2023)
  • Table 79. MEA Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 80. MEA Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 81. MEA Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 82. Middle East Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 83. Middle East Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 84. Middle East Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 85. Africa Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 86. Africa Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 87. Africa Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 88. North America Hemostatic Agents, by Country USD Million (2018-2023)
  • Table 89. North America Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 90. North America Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 91. North America Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 92. United States Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 93. United States Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 94. United States Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 95. Canada Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 96. Canada Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 97. Canada Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 98. Mexico Hemostatic Agents, by Type USD Million (2018-2023)
  • Table 99. Mexico Hemostatic Agents, by Application USD Million (2018-2023)
  • Table 100. Mexico Hemostatic Agents, by End-User USD Million (2018-2023)
  • Table 101. Hemostatic Agents Sales: by Type(K Tons)
  • Table 102. Hemostatic Agents Sales Passive Agents [Collagen, Cellulose, Gelatin, Polysaccharide hemospheres] , by Region K Tons (2018-2023)
  • Table 103. Hemostatic Agents Sales Active Agents [Thrombin, FloSeal, Sealants] , by Region K Tons (2018-2023)
  • Table 104. Hemostatic Agents Sales Newer Hemostatic Agents [Chitosan, Hemostatic Solutions] , by Region K Tons (2018-2023)
  • Table 105. Hemostatic Agents Sales: by Application(K Tons)
  • Table 106. Hemostatic Agents Sales Cardiology , by Region K Tons (2018-2023)
  • Table 107. Hemostatic Agents Sales Trauma , by Region K Tons (2018-2023)
  • Table 108. Hemostatic Agents Sales General Surgery , by Region K Tons (2018-2023)
  • Table 109. Hemostatic Agents Sales Transplant , by Region K Tons (2018-2023)
  • Table 110. Hemostatic Agents Sales Orthopedic , by Region K Tons (2018-2023)
  • Table 111. Hemostatic Agents Sales Plastic Surgery , by Region K Tons (2018-2023)
  • Table 112. Hemostatic Agents Sales Dental , by Region K Tons (2018-2023)
  • Table 113. Hemostatic Agents Sales Others , by Region K Tons (2018-2023)
  • Table 114. Hemostatic Agents Sales: by End-User(K Tons)
  • Table 115. Hemostatic Agents Sales Hospitals , by Region K Tons (2018-2023)
  • Table 116. Hemostatic Agents Sales Clinics , by Region K Tons (2018-2023)
  • Table 117. Hemostatic Agents Sales Ambulatory Surgical Centers , by Region K Tons (2018-2023)
  • Table 118. South America Hemostatic Agents Sales, by Country K Tons (2018-2023)
  • Table 119. South America Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 120. South America Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 121. South America Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 122. Brazil Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 123. Brazil Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 124. Brazil Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 125. Argentina Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 126. Argentina Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 127. Argentina Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 128. Rest of South America Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 129. Rest of South America Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 130. Rest of South America Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 131. Asia Pacific Hemostatic Agents Sales, by Country K Tons (2018-2023)
  • Table 132. Asia Pacific Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 133. Asia Pacific Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 134. Asia Pacific Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 135. China Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 136. China Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 137. China Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 138. Japan Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 139. Japan Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 140. Japan Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 141. India Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 142. India Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 143. India Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 144. South Korea Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 145. South Korea Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 146. South Korea Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 147. Taiwan Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 148. Taiwan Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 149. Taiwan Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 150. Australia Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 151. Australia Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 152. Australia Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 153. Rest of Asia-Pacific Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 154. Rest of Asia-Pacific Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 155. Rest of Asia-Pacific Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 156. Europe Hemostatic Agents Sales, by Country K Tons (2018-2023)
  • Table 157. Europe Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 158. Europe Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 159. Europe Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 160. Germany Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 161. Germany Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 162. Germany Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 163. France Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 164. France Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 165. France Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 166. Italy Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 167. Italy Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 168. Italy Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 169. United Kingdom Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 170. United Kingdom Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 171. United Kingdom Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 172. Netherlands Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 173. Netherlands Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 174. Netherlands Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 175. Rest of Europe Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 176. Rest of Europe Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 177. Rest of Europe Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 178. MEA Hemostatic Agents Sales, by Country K Tons (2018-2023)
  • Table 179. MEA Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 180. MEA Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 181. MEA Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 182. Middle East Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 183. Middle East Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 184. Middle East Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 185. Africa Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 186. Africa Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 187. Africa Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 188. North America Hemostatic Agents Sales, by Country K Tons (2018-2023)
  • Table 189. North America Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 190. North America Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 191. North America Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 192. United States Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 193. United States Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 194. United States Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 195. Canada Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 196. Canada Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 197. Canada Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 198. Mexico Hemostatic Agents Sales, by Type K Tons (2018-2023)
  • Table 199. Mexico Hemostatic Agents Sales, by Application K Tons (2018-2023)
  • Table 200. Mexico Hemostatic Agents Sales, by End-User K Tons (2018-2023)
  • Table 201. Hemostatic Agents: by Type(USD/Units)
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Company Basic Information, Sales Area and Its Competitors
  • Table 211. Company Basic Information, Sales Area and Its Competitors
  • Table 212. Company Basic Information, Sales Area and Its Competitors
  • Table 213. Hemostatic Agents: by Type(USD Million)
  • Table 214. Hemostatic Agents Passive Agents [Collagen, Cellulose, Gelatin, Polysaccharide hemospheres] , by Region USD Million (2025-2030)
  • Table 215. Hemostatic Agents Active Agents [Thrombin, FloSeal, Sealants] , by Region USD Million (2025-2030)
  • Table 216. Hemostatic Agents Newer Hemostatic Agents [Chitosan, Hemostatic Solutions] , by Region USD Million (2025-2030)
  • Table 217. Hemostatic Agents: by Application(USD Million)
  • Table 218. Hemostatic Agents Cardiology , by Region USD Million (2025-2030)
  • Table 219. Hemostatic Agents Trauma , by Region USD Million (2025-2030)
  • Table 220. Hemostatic Agents General Surgery , by Region USD Million (2025-2030)
  • Table 221. Hemostatic Agents Transplant , by Region USD Million (2025-2030)
  • Table 222. Hemostatic Agents Orthopedic , by Region USD Million (2025-2030)
  • Table 223. Hemostatic Agents Plastic Surgery , by Region USD Million (2025-2030)
  • Table 224. Hemostatic Agents Dental , by Region USD Million (2025-2030)
  • Table 225. Hemostatic Agents Others , by Region USD Million (2025-2030)
  • Table 226. Hemostatic Agents: by End-User(USD Million)
  • Table 227. Hemostatic Agents Hospitals , by Region USD Million (2025-2030)
  • Table 228. Hemostatic Agents Clinics , by Region USD Million (2025-2030)
  • Table 229. Hemostatic Agents Ambulatory Surgical Centers , by Region USD Million (2025-2030)
  • Table 230. South America Hemostatic Agents, by Country USD Million (2025-2030)
  • Table 231. South America Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 232. South America Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 233. South America Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 234. Brazil Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 235. Brazil Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 236. Brazil Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 237. Argentina Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 238. Argentina Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 239. Argentina Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 240. Rest of South America Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 241. Rest of South America Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 242. Rest of South America Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 243. Asia Pacific Hemostatic Agents, by Country USD Million (2025-2030)
  • Table 244. Asia Pacific Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 245. Asia Pacific Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 246. Asia Pacific Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 247. China Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 248. China Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 249. China Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 250. Japan Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 251. Japan Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 252. Japan Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 253. India Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 254. India Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 255. India Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 256. South Korea Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 257. South Korea Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 258. South Korea Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 259. Taiwan Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 260. Taiwan Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 261. Taiwan Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 262. Australia Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 263. Australia Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 264. Australia Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 265. Rest of Asia-Pacific Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 266. Rest of Asia-Pacific Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 267. Rest of Asia-Pacific Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 268. Europe Hemostatic Agents, by Country USD Million (2025-2030)
  • Table 269. Europe Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 270. Europe Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 271. Europe Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 272. Germany Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 273. Germany Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 274. Germany Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 275. France Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 276. France Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 277. France Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 278. Italy Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 279. Italy Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 280. Italy Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 281. United Kingdom Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 282. United Kingdom Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 283. United Kingdom Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 284. Netherlands Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 285. Netherlands Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 286. Netherlands Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 287. Rest of Europe Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 288. Rest of Europe Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 289. Rest of Europe Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 290. MEA Hemostatic Agents, by Country USD Million (2025-2030)
  • Table 291. MEA Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 292. MEA Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 293. MEA Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 294. Middle East Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 295. Middle East Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 296. Middle East Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 297. Africa Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 298. Africa Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 299. Africa Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 300. North America Hemostatic Agents, by Country USD Million (2025-2030)
  • Table 301. North America Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 302. North America Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 303. North America Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 304. United States Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 305. United States Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 306. United States Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 307. Canada Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 308. Canada Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 309. Canada Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 310. Mexico Hemostatic Agents, by Type USD Million (2025-2030)
  • Table 311. Mexico Hemostatic Agents, by Application USD Million (2025-2030)
  • Table 312. Mexico Hemostatic Agents, by End-User USD Million (2025-2030)
  • Table 313. Hemostatic Agents Sales: by Type(K Tons)
  • Table 314. Hemostatic Agents Sales Passive Agents [Collagen, Cellulose, Gelatin, Polysaccharide hemospheres] , by Region K Tons (2025-2030)
  • Table 315. Hemostatic Agents Sales Active Agents [Thrombin, FloSeal, Sealants] , by Region K Tons (2025-2030)
  • Table 316. Hemostatic Agents Sales Newer Hemostatic Agents [Chitosan, Hemostatic Solutions] , by Region K Tons (2025-2030)
  • Table 317. Hemostatic Agents Sales: by Application(K Tons)
  • Table 318. Hemostatic Agents Sales Cardiology , by Region K Tons (2025-2030)
  • Table 319. Hemostatic Agents Sales Trauma , by Region K Tons (2025-2030)
  • Table 320. Hemostatic Agents Sales General Surgery , by Region K Tons (2025-2030)
  • Table 321. Hemostatic Agents Sales Transplant , by Region K Tons (2025-2030)
  • Table 322. Hemostatic Agents Sales Orthopedic , by Region K Tons (2025-2030)
  • Table 323. Hemostatic Agents Sales Plastic Surgery , by Region K Tons (2025-2030)
  • Table 324. Hemostatic Agents Sales Dental , by Region K Tons (2025-2030)
  • Table 325. Hemostatic Agents Sales Others , by Region K Tons (2025-2030)
  • Table 326. Hemostatic Agents Sales: by End-User(K Tons)
  • Table 327. Hemostatic Agents Sales Hospitals , by Region K Tons (2025-2030)
  • Table 328. Hemostatic Agents Sales Clinics , by Region K Tons (2025-2030)
  • Table 329. Hemostatic Agents Sales Ambulatory Surgical Centers , by Region K Tons (2025-2030)
  • Table 330. South America Hemostatic Agents Sales, by Country K Tons (2025-2030)
  • Table 331. South America Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 332. South America Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 333. South America Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 334. Brazil Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 335. Brazil Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 336. Brazil Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 337. Argentina Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 338. Argentina Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 339. Argentina Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 340. Rest of South America Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 341. Rest of South America Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 342. Rest of South America Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 343. Asia Pacific Hemostatic Agents Sales, by Country K Tons (2025-2030)
  • Table 344. Asia Pacific Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 345. Asia Pacific Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 346. Asia Pacific Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 347. China Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 348. China Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 349. China Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 350. Japan Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 351. Japan Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 352. Japan Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 353. India Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 354. India Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 355. India Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 356. South Korea Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 357. South Korea Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 358. South Korea Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 359. Taiwan Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 360. Taiwan Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 361. Taiwan Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 362. Australia Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 363. Australia Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 364. Australia Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 365. Rest of Asia-Pacific Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 366. Rest of Asia-Pacific Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 367. Rest of Asia-Pacific Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 368. Europe Hemostatic Agents Sales, by Country K Tons (2025-2030)
  • Table 369. Europe Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 370. Europe Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 371. Europe Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 372. Germany Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 373. Germany Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 374. Germany Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 375. France Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 376. France Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 377. France Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 378. Italy Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 379. Italy Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 380. Italy Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 381. United Kingdom Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 382. United Kingdom Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 383. United Kingdom Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 384. Netherlands Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 385. Netherlands Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 386. Netherlands Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 387. Rest of Europe Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 388. Rest of Europe Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 389. Rest of Europe Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 390. MEA Hemostatic Agents Sales, by Country K Tons (2025-2030)
  • Table 391. MEA Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 392. MEA Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 393. MEA Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 394. Middle East Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 395. Middle East Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 396. Middle East Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 397. Africa Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 398. Africa Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 399. Africa Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 400. North America Hemostatic Agents Sales, by Country K Tons (2025-2030)
  • Table 401. North America Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 402. North America Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 403. North America Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 404. United States Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 405. United States Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 406. United States Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 407. Canada Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 408. Canada Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 409. Canada Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 410. Mexico Hemostatic Agents Sales, by Type K Tons (2025-2030)
  • Table 411. Mexico Hemostatic Agents Sales, by Application K Tons (2025-2030)
  • Table 412. Mexico Hemostatic Agents Sales, by End-User K Tons (2025-2030)
  • Table 413. Hemostatic Agents: by Type(USD/Units)
  • Table 414. Research Programs/Design for This Report
  • Table 415. Key Data Information from Secondary Sources
  • Table 416. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hemostatic Agents: by Type USD Million (2018-2023)
  • Figure 5. Global Hemostatic Agents: by Application USD Million (2018-2023)
  • Figure 6. Global Hemostatic Agents: by End-User USD Million (2018-2023)
  • Figure 7. South America Hemostatic Agents Share (%), by Country
  • Figure 8. Asia Pacific Hemostatic Agents Share (%), by Country
  • Figure 9. Europe Hemostatic Agents Share (%), by Country
  • Figure 10. MEA Hemostatic Agents Share (%), by Country
  • Figure 11. North America Hemostatic Agents Share (%), by Country
  • Figure 12. Global Hemostatic Agents: by Type K Tons (2018-2023)
  • Figure 13. Global Hemostatic Agents: by Application K Tons (2018-2023)
  • Figure 14. Global Hemostatic Agents: by End-User K Tons (2018-2023)
  • Figure 15. South America Hemostatic Agents Share (%), by Country
  • Figure 16. Asia Pacific Hemostatic Agents Share (%), by Country
  • Figure 17. Europe Hemostatic Agents Share (%), by Country
  • Figure 18. MEA Hemostatic Agents Share (%), by Country
  • Figure 19. North America Hemostatic Agents Share (%), by Country
  • Figure 20. Global Hemostatic Agents: by Type USD/Units (2018-2023)
  • Figure 21. Global Hemostatic Agents share by Players 2023 (%)
  • Figure 22. Global Hemostatic Agents share by Players (Top 3) 2023(%)
  • Figure 23. Global Hemostatic Agents share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2023
  • Figure 27. Baxter International Incorporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. Baxter International Incorporation (United States) Revenue: by Geography 2023
  • Figure 29. C.R. Bard Incorporation (United States) Revenue, Net Income and Gross profit
  • Figure 30. C.R. Bard Incorporation (United States) Revenue: by Geography 2023
  • Figure 31. B.Braun Melsungen AG (Germany) Revenue, Net Income and Gross profit
  • Figure 32. B.Braun Melsungen AG (Germany) Revenue: by Geography 2023
  • Figure 33. Advanced Medical Solutions Group (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. Advanced Medical Solutions Group (United Kingdom) Revenue: by Geography 2023
  • Figure 35. CuraMedical B.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 36. CuraMedical B.V. (Netherlands) Revenue: by Geography 2023
  • Figure 37. Stryker (United States) Revenue, Net Income and Gross profit
  • Figure 38. Stryker (United States) Revenue: by Geography 2023
  • Figure 39. Integra Life Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 40. Integra Life Sciences (United States) Revenue: by Geography 2023
  • Figure 41. Becton Dickinson (United States) Revenue, Net Income and Gross profit
  • Figure 42. Becton Dickinson (United States) Revenue: by Geography 2023
  • Figure 43. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 45. Medtrade Products Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 46. Medtrade Products Ltd (United Kingdom) Revenue: by Geography 2023
  • Figure 47. Global Hemostatic Agents: by Type USD Million (2025-2030)
  • Figure 48. Global Hemostatic Agents: by Application USD Million (2025-2030)
  • Figure 49. Global Hemostatic Agents: by End-User USD Million (2025-2030)
  • Figure 50. South America Hemostatic Agents Share (%), by Country
  • Figure 51. Asia Pacific Hemostatic Agents Share (%), by Country
  • Figure 52. Europe Hemostatic Agents Share (%), by Country
  • Figure 53. MEA Hemostatic Agents Share (%), by Country
  • Figure 54. North America Hemostatic Agents Share (%), by Country
  • Figure 55. Global Hemostatic Agents: by Type K Tons (2025-2030)
  • Figure 56. Global Hemostatic Agents: by Application K Tons (2025-2030)
  • Figure 57. Global Hemostatic Agents: by End-User K Tons (2025-2030)
  • Figure 58. South America Hemostatic Agents Share (%), by Country
  • Figure 59. Asia Pacific Hemostatic Agents Share (%), by Country
  • Figure 60. Europe Hemostatic Agents Share (%), by Country
  • Figure 61. MEA Hemostatic Agents Share (%), by Country
  • Figure 62. North America Hemostatic Agents Share (%), by Country
  • Figure 63. Global Hemostatic Agents: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Johnson & Johnson Services, Inc. (United States)
  • Baxter International Incorporation (United States)
  • C.R. Bard Incorporation (United States)
  • B.Braun Melsungen AG (Germany)
  • Advanced Medical Solutions Group (United Kingdom)
  • CuraMedical B.V. (Netherlands)
  • Stryker (United States)
  • Integra Life Sciences (United States)
  • Becton Dickinson (United States)
  • Pfizer Inc. (United States)
  • Medtrade Products Ltd (United Kingdom)
Additional players considered in the study are as follows:
Integra Life Sciences (United States) , Medtronic (Ireland) , CryoLife Inc. (United States) , LinxObere Medizintechnik GmbH (Germany)
Select User Access Type

Key Highlights of Report


Mar 2024 245 Pages 53 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hemostatic Agents Quantitative research analysis
Global Hemostatic Agents Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Hemostatic Agents market are Johnson & Johnson Services, Inc. (United States), Baxter International Incorporation (United States), C.R. Bard Incorporation (United States), B.Braun Melsungen AG (Germany), Advanced Medical Solutions Group (United Kingdom), CuraMedical B.V. (Netherlands), Stryker (United States), Integra Life Sciences (United States), Becton Dickinson (United States), Pfizer Inc. (United States) and Medtrade Products Ltd (United Kingdom), to name a few.
"Rising Healthcare Expenditures" is seen as one of major influencing trends for Hemostatic Agents Market during projected period 2023-2030.
Passive Agents [Collagen, Cellulose, Gelatin, Polysaccharide hemospheres] segment in Global market to hold robust market share owing to "Rise in Surgical Procedures ".

Know More About Global Hemostatic Agents Report?

Have a Query? Click Here

Other Related Reports

Herbal Medicines Comprehensive Study by Type (Medicinal Part, Medicine Function, Active Ingredient), Application (Western Herbalism, Traditional Chinese Medicine, Others), Sales Channel (Online, Offl...
$ 3500
Albendazole Comprehensive Study by Type (Capsule, Tablet), Application (Flatworms, Nematodes, Giardiasis, Microsporidiosis, Granulomatous Amoebic Encephalitis, Arthropods, Others), Distribution Chann...
$ 3450
Axillary Hyperhidrosis Drug Comprehensive Study by Type (Prescription Antiperspirant, Nerve-blocking Medications, Antidepressants, Botulinum Toxin Injections, Others), Application (Clinic, Hospital, ...
$ 3750
Heparin Calcium Comprehensive Study by Type (Unfractionated Heparin, Low molecular Heparin API), Application (Heart Attacks and Bypass Surgeries, Kidney Dialysis Processes, Extracorporeal Life Suppo...
$ 3650
Nanostructured Drug Comprehensive Study by Type (Liposomes, Polymeric Micelles, Solid Lipid Nanoparticles, Microemulsion and Nanoemulsion, Nanosuspension), Application (Cardiovascular/Chronic, Immuno...
$ 3650
Vegetable Capsules Comprehensive Study by Type (HPMC with Gelling Agent, HPMC without Gelling Agent, Plant Polysaccarides, Starch, Pullulan), Application (Supplements, Medicine, Cosmetics), End Use...
$ 3450